{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Unstable or life threatening cardiac events: myocardial infarction, hospitalization', 'for unstable angina, stroke, and other cardiovascular events considered life- or', 'intensively health-threatening by the study physician.', 'COPD Exacerbations: Subjects with two moderate or one severe COPD', 'exacerbation during the study.', 'Withdrawal from study treatment requires withdrawal from the study.', \"Non-Compliance with Study treatment: Subjects' compliance with study treatment\", 'will be assessed at each study visit. Subjects who are non-compliant should be re-', 'educated on the requirement for treatment compliance. Every effort will be made to', 'keep subjects in the study and to re-educate those subjects who continue to be non-', 'compliant. Subjects who continue to be non-compliant after multiple visit', 'assessments may be permanently discontinued after consultation with the GSK', 'clinical team.', 'Non-Compliance with eDiary: Subjects must be compliant in completing their', 'eDiary between each pair of on-treatment visits. Subjects who are non-compliant', 'should be re-educated on the requirement for daily diary entry compliance. Subjects', 'who continue to be non-compliant after multiple visit assessments may be', 'permanently discontinued after consultation with the GSK clinical team.', 'Subjects withdrawn from study treatment will not be replaced.', 'The following actions must be taken in relation to a subject who fails to attend the clinic', 'for a required study visit:', 'The site must attempt to contact the subject and re-schedule the missed visit as', 'soon as possible.', 'The site must counsel the subject on the importance of maintaining the assigned', 'visit schedule and ascertain whether or not the subject wishes to and/or should', 'continue in the study.', 'In cases where the subject is deemed \"lost to follow up\\', the investigator or', 'designee must make every effort to regain contact with the subject (where', \"possible, 3 telephone calls and if necessary a certified letter to the subject's last\", 'known mailing address or local equivalent methods). These contact attempts', \"should be documented in the subject's medical record.\", 'Should the subject continue to be unreachable, only then will he/she be considered', 'to have withdrawn from the study with a primary reason of \"Lost to Follow-up\"', '5.5.2.', 'Reason for Study Withdrawal', 'The primary reason for study withdrawal will be recorded in the eCRF. When a subject', 'withdraws consent, the investigator must document the reason (if specified by the', 'subject) in the eCRF.', 'The primary reason for study withdrawal may include:', 'Adverse event', '33']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Lost to follow-up', 'Withdrew consent', 'subject relocated', 'frequency of visits', 'burden of procedures', 'other (specify)', 'Protocol deviation', 'Lack of efficacy', 'COPD exacerbation', 'Study closed/terminated', 'Subject reached protocol-defined stopping criteria', 'Pregnancy', 'Investigator discretion', '5.5.3.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to', 'assure subject safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance).', 'http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid', 'ances/UCM174090.pdf', 'Phase III-IV Liver Chemistry Increased Monitoring Algorithm with Continued', 'Therapy for ALT >3xULN but <8xULN', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', 'Continue Study Treatment and Monitor Liver Chemistry', 'ALT >5xULN', 'Yes', '`No', 'ALT <5xULN', 'Yes', 'No', 'Persists for', 'Persists for', 'Yes', 'Able to', '2 weeks', 'Yes', 'Able to', '>4 weeks', 'monitor', 'or other', 'monitor', 'or other', 'ALT>5xULN', 'Yes', 'weekly', 'Yes', 'stopping', 'No', 'ALT >3xULN', 'Yes', 'weekly', 'Yes', 'stopping', 'but <8xULN', 'for >2', 'criteria', 'but <5xULN', 'for >4', 'criteria', '+ bili <2xULN +', 'weeks', 'met', '+ bili <2xULN +', 'weeks', 'met', 'no symptoms', 'no symptoms', 'No', 'Yes', 'No', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', \"Reportas an SAE if possible Hy's Law case: ALT>3xULN and Bilirubin>2xULN (>35% direct) or\", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', '34']\n\n###\n\n", "completion": "END"}